Stocks TelegraphStocks Telegraph
Stock Ideas

VERA Financial Statements and Analysis

NASDAQ : VERA

Vera Therapeutics

$53.93
2.71+5.29%
Open: 3:00 PM
61.4
BESG ScoreESG Rating

FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

DateSep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024Jun 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20252025202520242024
periodQ3Q2Q1Q3Q2
revenueN/A0000
cost of revenue564.00K563.00K000
gross profit-564.00K-563.00K000
gross profit ratio00000
research and development expenses56.344M58.076M41.278M40.314M29.311M
general and administrative expensesN/A21.946M14.58M9.487M8.032M
selling and marketing expensesN/A01.336M00
selling general and administrative expenses27.024M21.946M15.916M9.487M8.032M
other expenses0-444.00K00450.00K
operating expenses83.368M79.578M57.194M49.801M37.343M
cost and expenses83.932M80.141M57.194M49.801M37.343M
interest income5.736M6.32M6.906M4.761M5.104M
interest expense1.96M1.874M1.792M1.936M1.912M
depreciation and amortization564.00K563.00K85.00K24.00K1.495M
ebitda-77.769M-74.094M-49.817M-44.672M-31.796M
ebitda ratio00000
operating income-83.932M-80.141M-57.194M-49.801M-37.343M
operating income ratio00000
total other income expenses net3.639M3.61M5.50M3.169M3.635M
income before tax-80.293M-76.531M-51.694M-46.632M-33.708M
income before tax ratio00000
income tax expenseN/A0000
net income-80.293M-76.531M-51.694M-46.632M-33.708M
net income ratio00000
eps-1.26-1.20-0.81-0.85-0.62
eps diluted-1.26-1.20-0.81-0.85-0.62
weighted average shs out63.847M63.789M63.672M54.898M54.729M
weighted average shs out dil63.847M63.789M63.672M54.898M54.729M
Graph

Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

DateSep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024Jun 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20252025202520242024
periodQ3Q2Q1Q3Q2
cash and cash equivalents57.773M49.121M55.09M27.256M25.085M
short term investments439.616M507.706M534.744M326.053M359.302M
cash and short term investments497.389M556.827M589.834M353.309M384.387M
net receivables3.357M4.202M3.586M01.96M
inventory00000
other current assets5.485M10.325M12.656M10.822M8.40M
total current assets506.231M571.354M606.076M364.131M389.503M
property plant equipment net3.191M3.622M3.977M4.289M2.084M
goodwill00000
intangible assets00000
goodwill and intangible assets00000
long term investments00000
tax assets00000
other non current assets8.081M3.552M114.00K140.00K5.704M
total non current assets11.272M7.174M4.091M4.429M7.788M
other assets00000
total assets517.503M578.528M610.167M368.56M397.291M
account payables17.95M13.157M9.262M4.602M4.664M
short term debt473.00K855.00K1.191M1.872M4.232M
tax payables00000
deferred revenue00000
other current liabilities23.457M19.542M11.441M19.99M9.522M
total current liabilities41.88M33.554M21.894M26.464M18.418M
long term debt76.743M76.697M53.274M53.038M50.718M
deferred revenue non current00000
deferred tax liabilities non current00000
other non current liabilities0000286.00K
total non current liabilities76.743M76.697M53.274M53.038M51.004M
other liabilities00000
capital lease obligations03.088M3.557M4.44M455.00K
total liabilities118.623M110.251M75.168M79.502M69.422M
preferred stock00000
common stock64.00K64.00K64.00K55.00K55.00K
retained earnings-669.768M-589.475M-512.944M-417.825M-371.193M
accumulated other comprehensive income loss881.00K527.00K654.00K1.044M-450.00K
other total stockholders equity1.068B1.057B1.047B705.784M699.457M
total stockholders equity398.88M468.277M534.999M289.058M327.869M
total equity398.88M468.277M534.999M289.058M327.869M
total liabilities and stockholders equity517.503M578.528M610.167M368.56M397.291M
minority interest00000
total investments439.616M507.706M534.744M326.053M359.302M
total debt77.216M77.552M54.465M54.91M52.834M
net debt19.443M28.431M-625.00K27.654M27.749M
Graph

Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

DateSep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024Jun 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20252025202520242024
periodQ3Q2Q1Q3Q2
deferred income tax00000
stock based compensation9.745M9.472M7.744M5.588M4.873M
change in working capital8.686M13.382M-9.438M2.475M6.144M
accounts receivables00000
inventory00000
accounts payables4.793M3.895M1.597M-62.00K-545.00K
other working capital3.893M9.487M-11.035M-3.979M6.689M
other non cash items-173.00K-1.24M-1.103M2.177M3.327M
net cash provided by operating activities-61.906M-54.798M-54.406M-36.885M-24.782M
investments in property plant and equipment-133.00K-208.00K-187.00K-25.109M24.782M
acquisitions net00000
purchases of investments-98.696M-94.728M-89.992M-79.851M-81.088M
sales maturities of investments168.59M126.061M106.246M111.50M58.50M
other investing activites0-2.581M-750.00K31.777M-89.00K
net cash used for investing activites69.761M28.544M15.317M38.317M-22.677M
debt repayment019.821M000
common stock issued0464.00K07.521M3.439M
common stock repurchased000-13.00K0
dividends paid00000
other financing activites797.00K01.533M-6.769M3.439M
net cash used provided by financing activities797.00K20.285M1.533M739.00K3.439M
effect of forex changes on cash00000
net change in cash8.652M-5.969M-37.556M2.171M-44.02M
cash at end of period57.773M49.121M55.09M27.256M25.085M
cash at beginning of period49.121M55.09M92.646M25.085M69.105M
operating cashflow-61.906M-54.798M-54.406M-36.885M-24.782M
capital expenditure-133.00K-208.00K-187.00K-25.109M24.782M
free cash flow-62.039M-55.006M-54.593M-61.994M0
Graph

Frequently Asked Questions

How did Vera Therapeutics, Inc. do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, VERA generated - in revenue last quarter, while its costs came in at $564.00K.
Last quarter, how much Gross Profit did Vera Therapeutics, Inc. report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Vera Therapeutics, Inc. reported a -$564.00K Gross Profit for the quarter ended Sep 30, 2025.
Have VERA's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. VERA incurred $83.37M worth of Operating Expenses, while it generated -$83.93M worth of Operating Income.
How much Net Income has VERA posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Vera Therapeutics, Inc., the company generated -$80.29M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did Vera Therapeutics, Inc. have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Vera Therapeutics, Inc. as of the end of the last quarter was $57.77M.
What are VERA's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, VERA had Total Net Receivables of $3.36M.
In terms of Total Assets and Current Assets, where did Vera Therapeutics, Inc. stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of VERA were $506.23M, while the Total Assets stand at $517.50M.
As of the last quarter, how much Total Debt did Vera Therapeutics, Inc. have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of VERA's debt was $77.22M at the end of the last quarter.
What were VERA's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, VERA reported total liabilities of $118.62M.
How much did VERA's Working Capital change over the last quarter?
Working Capital Change for VERA was $8.69M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
VERA generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. VERA generated -$61.91M of Cash from Operating Activities during its recently reported quarter.
What was VERA's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. VERA reported a $8.65M Net Change in Cash in the most recent quarter.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph